Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the Annual General Meeting (AGM) of Shareholders held on June 19, 2025. The report details the voting results on the 2024 financial statements, compensation reports, board elections, and the appropriation of losses for the fiscal year ended December 31, 2024.
Key Financial Metrics
- Net Loss (2024): CHF 45,848K.
- Accumulated Losses: Increased from CHF 310,998K to CHF 356,846K following the appropriation of the 2024 loss.
- Board Compensation Cap (2025-2026): CHF 1,029K (excluding employer social security contributions).
- Executive Committee Compensation Cap (2026): CHF 7,496K (excluding employer social security contributions).
- Revenue, Cash Flow, and Debt: The filing text does not provide specific values for revenue, operating cash flow, or debt levels.
Material Changes and Governance Actions
Shareholders approved the 2024 IFRS Consolidated and Statutory Financial Statements and endorsed the 2024 Compensation Report. The Board of Directors and Executive Committee were granted discharge for the 2024 financial year. Notably, agenda items 6.1 and 6.2 were withdrawn by the Board prior to the meeting.
Significant governance changes include:
- Board Re-elections: Monika Büttler, Carl June, Andrea Pfeifer, and Roy Twyman were re-elected.
- New Board Appointments: Renée Aguiar-Lucander was elected as a Board Member. Martin Zügel was elected as a Board Member and Chair of the Board.
- Committee Updates: Martin Zügel was also elected to the Compensation, Nomination and Corporate Governance Committee.
- Auditor and Proxy: PricewaterhouseCoopers SA was re-elected as statutory auditor for 2025, and Reymond & Associés Attorneys was re-elected as Independent Proxy.
Outlook and Risks
The filing does not contain specific forward-looking guidance, management commentary on future operations, or a discussion of risks and contingencies beyond the standard incorporation by reference into registration statements. The primary focus is the ratification of past performance and the establishment of governance structures for the upcoming year.
Investor Verification Checklist
- Verify the detailed minutes of the AGM on the company website (https://ir.acimmune.com/governance) within 15 days of the meeting.
- Review the attached Exhibit 99.1 (Management Presentation) for operational updates not included in this summary.
- Confirm the impact of the withdrawn agenda items (6.1 and 6.2) on future corporate strategy.
- Monitor the company's cash burn rate given the continued accumulation of losses (CHF 356.8M total).